For breast cancer, immune checkpoint inhibitors have shown improved clinical outcomes, especially in the basal-like subtype (33–35); an increased baseline density of CD8+ T cells is associated with a favorable response to immunotherapy (36). Here, CD8A is linked to breast carcinoma.